Table 2.
Trials to assess the efficacy of moxetumumab pasudotox in patients with classic hairy cell leukemia.
| Trial | Phase | Drugs | Disease Status | Patients | ORR (%) | CR (%) | MRD Free (%) |
|---|---|---|---|---|---|---|---|
| Kreitman et al. [41] | I | Moxe (5–40 µg/kg) Moxe (50 µg/kg) |
Relapsed Relapsed |
16 33 |
86 88 |
57 64 |
n.a. 33 |
| Kreitman et al. [10,42] | III | Moxe (40 µg/kg) | Relapsed | 80 | 75 | 41 | 34 |
| NCT03805932 | I | Moxe (40 µg/kg) + R | Relapsed | 20 | ongoing | ongoing | ongoing |
ORR, overall response rate; CR, complete remission; MRD minimal residual disease; Moxe, moxetumumab pasudotox; R, rituximab.